checkAd

     129  0 Kommentare Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Seite 3

    Investor Contacts:
    Jason Kantor, Ph.D
    Nurix Therapeutics
    ir@nurixtx.com

    Elizabeth Wolffe, Ph.D
    Wheelhouse Life Science Advisors
    lwolffe@wheelhouselsa.com

    Lesen Sie auch

    Media Contact:
    Aljanae Reynolds
    Wheelhouse Life Science Advisors
    areynolds@wheelhouselsa.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Seite 3 SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) - Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer